Prevalence of Serotype 19A Streptococcus pneumoniae among Isolates from U.S. Children in 2005-2006 and Activity of Faropenem
Abstract
Prevalence of Serotype 19A Streptococcus pneumoniae among Isolates from U.S. Children in 2005-2006 and Activity of Faropenem ▿ Ian A. Critchley 1 , * , Michael R. Jacobs 2 , Steven D. Brown 3 , Maria M. Traczewski 3 , Glenn S. Tillotson 4 and Nebojsa Janjic 1 1 Replidyne, Inc., Louisville, Colorado 80027 2 Department of Pathology, Case Western Reserve University, and University Hospitals, Case Medical Center, Cleveland, Ohio 44106 3 Clinical Microbiology Institute, Wilsonville, Oregon 97070 4 Replidyne, Inc., Milford, Connecticut 06460 ABSTRACT Of 393 isolates of Streptococcus pneumoniae from U.S. children collected in 2005-2006, nonvaccine serotypes accounted for 89.1%, with serotype 19A the most prevalent, representing 30.5% of all isolates. The MIC 90 of faropenem against serotype 19A isolates was 1 μg/ml, compared to ≥8 μg/ml against amoxicillin/clavulanate, cefdinir, cefuroxime axetil, and azithromycin.